Combined with the ability of sorafenib to induce activation of Hedgehog signaling, this observation indicates that sorafenib might suppress MEKK2/3 to promote Hedgehog signaling activation, resulting in the upregulation of CD44, acquisition of a progenitor cell phenotype and sorafenib resistance in HCC cells. The gene discussed is CD44; the disease is hepatocellular carcinoma.